Early propranolol treatment induces lung heme-oxygenase-1, attenuates metabolic dysfunction, and improves survival following experimental sepsis

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Wilson, Joel ^a   Higgins, David ^a   Hutting, Haley ^a   Serkova, Natalie ^a   Baird, Christine ^a   Khailova, Ludmila ^a   Queensland, Kelly ^a   Vu Tran, Zung ^a   Weitzel, Lindsay ^a   Wischmeyer, Paul E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEME OXYGENASE; HMOX1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL SEPSIS; HEART RATE; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RAT; SEPSIS; SURVIVAL; ANIMAL; BIOSYNTHESIS; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; LUNG; METABOLIC DISEASES; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; HEME OXYGENASE (DECYCLIZING); LUNG; MALE; METABOLIC DISEASES; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84883626617     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12889     Document Type: Article

References (33)

1. Berk JL. Use of vasoactive drugs in the treatment of shock. The Surgical clinics of North America 1975, 55:721-728.
2. Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. The Journal of burn care & rehabilitation 1997, 18:223-227. 10.1097/00004630-199705000-00008, 9169945.
3. Breitenstein E, Chioléro RL, Jéquier E, Dayer P, Krupp S, Schutz Y. Effects of beta-blockade on energy metabolism following burns. Burns : journal of the International Society for Burn Injuries 1990, 16:259-264. 10.1016/0305-4179(90)90136-K, 2257068.
4. Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR. Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Annals of surgery 1988, 208:484-492. 10.1097/00000658-198810000-00010, 1493755, 3052328.
5. Minifee PK, Barrow RE, Abston S, Desai M, Herndon DN. Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism. Journal of pediatric surgery 1989, 24:806-810; discussion 810-801. 10.1016/S0022-3468(89)80541-X, 2769550.
6. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: propranolol. Critical care medicine 2007, 35:S616-620. 10.1097/01.CCM.0000278599.30298.80, 17713418.
7. Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. The Journal of trauma 2007, 62:676-681. 10.1097/TA.0b013e318031afd3, 17414346.
8. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-to-bedside review: Beta-adrenergic modulation in sepsis. Critical care (London, England) 2009, 13:230.
9. Oberbeck R, Kobbe P. Beta-adrenergic antagonists: indications and potential immunomodulatory side effects in the critically ill. Current medicinal chemistry 2009, 16:1082-1090. 10.2174/092986709787581770, 19275613.
10. Rudiger A. Beta-block the septic heart. Critical care medicine 2010, 38:S608-612.
11. Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, Santopinto M, Tognoni G. Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Critical care medicine 2012, 40:1-5.
12. Herndon DN, Dasu MR, Wolfe RR, Barrow RE. Gene expression profiles and protein balance in skeletal muscle of burned children after beta-adrenergic blockade. Am J Physiol Endocrinol Metab 2003, 285(4):E783-789.
13. Novotny NM, Lahm T, Markel TA, Crisostomo PR, Wang M, Wang Y, Ray R, Tan J, Al-Azzawi D, Meldrum DR. beta-Blockers in sepsis: reexamining the evidence. Shock (Augusta, Ga) 2009, 31:113-119.
14. Singleton KD, Wischmeyer PE. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. European surgical research Europäische chirurgische Forschung Recherches chirurgicales européennes 2003, 35:486-491.
15. Singleton KD, Wischmeyer PE. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. European surgical research Europaische chirurgische Forschung Recherches chirurgicales europeennes 2003, 35(6):486-491. 10.1159/000073387, 14593232.
16. Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, Maher JJ, Niemann CU. Metabolic profiling of livers and blood from obese Zucker rats. Journal of hepatology 2006, 44:956-962. 10.1016/j.jhep.2005.07.009, 16223541.
17. Kallweit AR, Baird CH, Stutzman DK, Wischmeyer PE. Glutamine prevents apoptosis in intestinal epithelial cells and induces differential protective pathways in heat and oxidant injury models. JPEN Journal of parenteral and enteral nutrition 2012, 36(5):551-555. 10.1177/0148607112445579, 22544840.
18. Singleton KD, Serkova N, Beckey VE, Wischmeyer PE. Glutamine attenuates lung injury and improves survival after sepsis: role of enhanced heat shock protein expression. Critical care medicine 2005, 33(6):1206-1213. 10.1097/01.CCM.0000166357.10996.8A, 15942332.
19. Kallweit AR, Baird CH, Stutzman DK, Wischmeyer PE. Glutamine prevents apoptosis in intestinal epithelial cells and induces differential protective pathways in heat and oxidant injury models. JPEN Journal of parenteral and enteral nutrition 2012, 36(5):551-555. 10.1177/0148607112445579, 22544840.
20. Al-Mousawi AM, Jeschke MG, Herndon DN. Beta blockade: the right time, the right dose, the right receptor!. Critical care medicine 2010, 38:688-689. 10.1097/CCM.0b013e3181c5861b, 20083925.
21. Ackland GL, Yao ST, Rudiger A, Dyson A, Stidwill R, Poputnikov D, Singer M, Gourine AV. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Critical care medicine 2010, 38:388-394. 10.1097/CCM.0b013e3181c03dfa, 19829100.
22. Schmitz D, Wilsenack K, Lendemanns S, Schedlowski M, Oberbeck R. beta-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 2007, 72:286-294. 10.1016/j.resuscitation.2006.07.001, 17118511.
23. Morelli A. Heart Rate Control With Esmolol in Septic Shock. ClinicalTrials.gov (Internet) Bethesda (MD): National Library of Medicine (US), Available from., http://clinicaltrials.gov/show/NCT01231698
24. Mori K, Morisaki H, Yajima S, Suzuki T, Ishikawa A, Nakamura N, Innami Y, Takeda J. Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. Intensive care medicine 2011, 37:1849-1856. 10.1007/s00134-011-2326-x, 21847651.
25. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, Takeda J. Infusion of the ??-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats*. Critical Care Medicine 2005, 33:2294-2301. 10.1097/01.CCM.0000182796.11329.3B, 16215384.
26. Galli F, Varga Z, Balla J, Ferraro B, Canestrari F, Floridi A, Kakuk G, Buoncristiani U. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney international Supplement 2001, 78:S148-154.
27. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock (Augusta, Ga) 2009, 31:515-520.
28. Lang CH, Nystrom G, Frost R. Beta-adrenergic blockade exacerbates sepsis-induced changes in tumor necrosis factor alpha and interleukin-6 in skeletal muscle and is associated with impaired translation initiation. The Journal of trauma 2008, 64:477-486. 10.1097/01.TA.0000249375.43015.01, 18301218.
29. Cavaillon J-M, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. Journal of endotoxin research 2006, 12:151-170. 10.1179/096805106X102246, 16719987.
30. Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA. Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. The American journal of physiology 1999, 276(3 Pt 1):L443-451.
31. Kvam E, Hejmadi V, Ryter S, Pourzand C, Tyrrell RM. Heme oxygenase activity causes transient hypersensitivity to oxidative ultraviolet A radiation that depends on release of iron from heme. Free radical biology & medicine 2000, 28(8):1191-1196. 10.1016/S0891-5849(00)00205-7, 10889448.
32. Constantin M, Choi AJS, Cloonan SM, Ryter SW. Therapeutic potential of heme oxygenase-1/carbon monoxide in lung disease. International journal of hypertension 2012, 2012:859235. 3296197, 22518295.
33. Tsoyi K, Lee TY, Lee YS, Kim HJ, Seo HG, Lee JH, Chang KC. Heme-Oxygenase-1 Induction and Carbon Monoxide- Releasing Molecule Inhibit Lipopolysaccharide (LPS) -Induced High-Mobility Group Box 1 Release in Vitro and Improve Survival of Mice in LPS- and Cecal Ligation and Puncture- Induced Sepsis Model in Vivo. 2009, 76:173-182.